Highlights frameworks for early lung cancer detection pathways which intersect with bronchoscopic diagnostic procedures in underserved populations.
Abstract
BACKGROUND: The clinical value of a negative low-dose computed tomography (LDCT) screen for long-term risk stratification remains unclear, leading to uncertainties in rescreening intervals. RESEARCH QUESTION: What are the long-term risks of lung cancer incidence and mortality among screening-negative individuals? STUDY DESIGN AND METHODS: This prospective cohort study utilized data from provincial initiatives (2012-2019) within China's National Lung Cancer Screening Program. Participants aged 40-74 years were categorized as non-screened, screening-negative, screening-positive, or low-risk. Inverse probability weighting integrated with Cox proportional hazard models was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for lung cancer incidence and mortality. RESULTS: During a median follow-up of 8.61 years, 3,173 incident lung cancers and 2,083 lung cancer deaths occurred among 269,173 participants. Compared with the non-screened group, the screening-negative group exhibited a significantly lower risk of lung cancer incidence (HR = 0.80, 95% CI: 0.65-0.97) and all-cause mortality (HR = 0.77, 95% CI: 0.70-0.85), whereas lung cancer-specific mortality did not differ significantly (HR = 0.88, 95% CI: 0.69-1.12). The reduced risk of lung cancer persisted throughout follow-up and was most pronounced during the first three years. While the screening-negative group exhibited lung cancer incidence (HR = 0.84, 95% CI: 0.68-1.03), lung cancer mortality (HR = 0.89, 95% CI: 0.69-1.15), and all-cause mortality (HR = 0.91, 95% CI: 0.80-1.05) comparable to those in the low-risk group, a slightly lower risk of lung cancer was observed in the screening-negative group at the 9-year cumulative follow-up. In stratified analyses, currently smoking individuals with negative screening results had a higher long-term risk of lung cancer incidence than those in the low-risk group. INTERPRETATION: Individuals with negative LDCT screening results had generally comparable long-term risks of lung cancer incidence, mortality, and all-cause mortality to the low-risk population, supporting risk-stratified follow-up rather than uniform annual rescreening.
Keep reading
N opens the next oneDirectly impacts IP practice by highlighting the critical role of bronchoscopic sampling techniques in providing adequate tissue for molecular profiling.
Highlights the critical importance of obtaining adequate tissue via bronchoscopic biopsies for comprehensive molecular profiling.
Relevant to ablative therapies often managed or co-evaluated by interventional pulmonologists in the multidisciplinary management of lung malignancies.
Relevant for IP specialists involved in the bronchoscopic and image-guided tissue diagnosis and staging of apical lung masses.
Relevant to IP practices managing pulmonary nodules discovered during staging or diagnostic workups.